Heart Test Laboratories, Inc.

NasdaqCM HSCS

Heart Test Laboratories, Inc. Gross Profit for the Trailing 12 Months (TTM) ending October 31, 2024: USD -36.10 K

Heart Test Laboratories, Inc. Gross Profit is USD -36.10 K for the Trailing 12 Months (TTM) ending October 31, 2024, a -101.54% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Heart Test Laboratories, Inc. Gross Profit for the Trailing 12 Months (TTM) ending October 31, 2023 was USD 2.35 M, a 262,726.17% change year over year.
Heart Test Laboratories, Inc. Gross Profit for the Trailing 12 Months (TTM) ending October 31, 2022 was USD -894.00.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

NasdaqCM: HSCS

Heart Test Laboratories, Inc.

CEO	Mr. Andrew Simpson
IPO Date	June 16, 2022
Location	United States
Headquarters	550 Reserve Street
Employees	15
Sector	Health Care
Industries Medical Instruments Telehealth

Description

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional 12-lead resting ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.

Key trends

Past 5 years